Novel CoQ10 Antidiabetic Mechanisms Underlie Its Positive Effect: Modulation of Insulin and Adiponectine Receptors, Tyrosine Kinase, PI3K, Glucose Transporters, sRAGE and Visfatin in Insulin Resistant/Diabetic Rats
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
UNLABELLED: As a nutritional supplement, coenzyme Q10 (CoQ10) was tested previously in several models of diabetes and/or insulin resistance (IR); however, its exact mechanisms have not been profoundly explicated. Hence, the objective of this work is to verify some of the possible mechanisms that underlie its therapeutic efficacy. Moreover, the study aimed to assess the potential modulatory effect of CoQ10 on the antidiabetic action of glimebiride. An insulin resistance/type 2 diabetic model was adopted, in which rats were fed high fat/high fructose diet (HFFD) for 6 weeks followed by a single sub-diabetogenic dose of streptozotocin (35 mg/kg, i.p.). At the end of the 7(th) week animals were treated with CoQ10 (20 mg/kg, p.o) and/or glimebiride (0.5 mg/kg, p.o) for 2 weeks. CoQ10 alone opposed the HFFD effect and increased the hepatic/muscular content/activity of tyrosine kinase (TK), phosphatidylinositol kinase (PI3K), and adiponectin receptors. Conversely, it decreased the content/activity of insulin receptor isoforms, myeloperoxidase and glucose transporters (GLUT4; 2). Besides, it lowered significantly the serum levels of glucose, insulin, fructosamine and HOMA index, improved the serum lipid panel and elevated the levels of glutathione, sRAGE and adiponectin. On the other hand, CoQ10 lowered the serum levels of malondialdehyde, visfatin, ALT and AST. Surprisingly, CoQ10 effect surpassed that of glimepiride in almost all the assessed parameters, except for glucose, fructosamine, TK, PI3K, and GLUT4. Combining CoQ10 with glimepiride enhanced the effect of the latter on the aforementioned parameters. CONCLUSION: These results provided a new insight into the possible mechanisms by which CoQ10 improves insulin sensitivity and adjusts type 2 diabetic disorder. These mechanisms involve modulation of insulin and adiponectin receptors, as well as TK, PI3K, glucose transporters, besides improving lipid profile, redox system, sRAGE, and adipocytokines. The study also points to the potential positive effect of CoQ10 as an adds- on to conventional antidiabetic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin
Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., et al. (2005) · Science · doi:10.1126/science.1097243 · Cited by 1,906
RetractedMatthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., Okada-Iwabu, M., Kawamoto, S., Kubota, N., Kubota, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1557 · Cited by 1,396 · cited 1×
“On the other hand, other studies [67,68] concluded that the decreased levels of adiponectin receptors participate in the development of hypoadiponectinemia with the consequent IR.”
BackgroundKrssak, M., Falk Petersen, K., Dresner, A., DiPietro, L., Vogel, S. M., Rothman, D. L., Shulman, G. I., & Roden, M. (1999) · Diabetologia · doi:10.1007/s001250051123 · Cited by 1,264 · cited 1×
“[65] and Shulman [66] stated that the elevated plasma FFAs and TGs in muscles lead to the development of muscle IR, events that correlate, even partially, to hypoadiponectenimea.”
BackgroundBiochemical Functions of Coenzyme Q 10
Crane, F. L. (2001) · Journal of the American College of Nutrition · doi:10.1080/07315724.2001.10719063 · Cited by 869
Vozarova, B., Stefan, N., Lindsay, R. S., Saremi, A., Pratley, R. E., Bogardus, C., & Tataranni, P. A. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1889 · Cited by 717
Stephens, J. M., Lee, J., & Pilch, P. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.2.971 · Cited by 553
Eriksson, J., Lindström, J., Valle, T., Aunola, S., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Lauhkonen, M., Lehto, P., et al. (1999) · Diabetologia · doi:10.1007/s001250051229 · Cited by 368 · cited 1×
“CoQ10 is known to be deficient in case of diabetes [6,7] and in some individuals with reduced energy expenditure and skeletal muscle dysfunction [22].”
BackgroundThe release of the adipocytokine visfatin is regulated by glucose and insulin
Haider, D. G., Schaller, G., Kapiotis, S., Maier, C., Luger, A., & Wolzt, M. (2006) · Diabetologia · doi:10.1007/s00125-006-0303-7 · Cited by 258 · cited 1×
“Another adipocytokine assessed in the current study was the pro-inflammatory visfatin, which was elevated significantly in the present model and previous studies [69], reporting its elevation in many inflammatory diseases including obesity, IR and type 2 diabetes [70].”
Result
Cited by
Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance
Fazakerley, D. J., Chaudhuri, R., Yang, P., Maghzal, G. J., Thomas, K. C., Krycer, J. R., Humphrey, S. J., Parker, B. L., Fisher-Wellman, K. H., Meoli, C. C., et al. (2018) · eLife · doi:10.7554/elife.32111 · Cited by 160
“While there are reports of CoQ supplementation benefitting these conditions (Amin et al., 2014; Ayer et al., 2015; Hodgson et al., 2002; Mortensen et al., 2014; Raygan et al., 2016), the efficacy of CoQ10 in the treatment of diabetes and cardiovascular diseases remains unclear (Ayer et al.”
BackgroundCoenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview
Mantle, D., & Hargreaves, I. (2019) · Antioxidants · doi:10.3390/antiox8020044 · Cited by 63
“Supplemental CoQ10 may benefit type II diabetes via several mechanisms, for example by promoting enhanced levels of cellular energy required for glucose metabolism, or via direct modulation of the expression of genes relevant to glucose metabolism, or via its antioxidant action [35].”
BackgroundZhang, S.-Y., Yang, K.-L., Zeng, L.-T., Wu, X.-H., & Huang, H.-Y. (2018) · International Journal of Endocrinology · doi:10.1155/2018/6484839 · Cited by 51
“coenzyme Q10 level is beneficial for this cycle [40].”
BackgroundCoenzyme Q10 Supplementation for Diabetes and Its Complications: An Overview
Mantle, D. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.149 · Cited by 21
Metadata
- Authors
- Amin, M. M., Asaad, G. F., Abdel Salam, R. M., El-Abhar, H. S., & Arbid, M. S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-20
- Volume
- 9
- Issue
- 2
- Pages
- e89169
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1991778157
- Cited by
- 82
- References
- 13
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel CoQ10 Antidiabetic Mechanisms Underlie Its Positive Effect: Modulation of Insulin and Adiponectine Receptors, Tyrosine Kinase, PI3K, Glucose Transporters, sRAGE and Visfatin in Insulin Resistant/Diabetic Rats. https://app.cochat.ai/papers/10.1371/journal.pone.0089169
- The paper
- Amin, M. M., Asaad, G. F., Abdel Salam, R. M., El-Abhar, H. S., & Arbid, M. S. (2014). Novel CoQ10 Antidiabetic Mechanisms Underlie Its Positive Effect: Modulation of Insulin and Adiponectine Receptors, Tyrosine Kinase, PI3K, Glucose Transporters, sRAGE and Visfatin in Insulin Resistant/Diabetic Rats. PLoS ONE. https://doi.org/10.1371/journal.pone.0089169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.